ArticleBMC infectious diseases2026
Association of IL-10 (rs1800896) and TLR3 (rs1879026) polymorphism with progression of hcv-related liver disease and hepatocellular carcinoma in Egyptian patients.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis C virus (HCV) is a significant global health concern, particularly in Egypt, where its prevalence is estimated at 4.5%-6.7%. The Egyptian genotype, HCV-4, accounts for most infections and is a leading cause of cirrhosis, chronic liver disease, and hepatocellular carcinoma (HCC). A previous study was conducted in Egypt to examine certain single-nucleotide polymorphisms (SNPs) in both toll-like receptor 3 (TLR3) and interleukin-10 (IL-10) and their association to interferon therapy. However, there is still a remaining gap to examine the correlation of both TLR3 and IL-10 gene polymorphism to the disease progression and disease prognosis among Egyptian genotype, HCV-4. This study investigates the relationship between toll-like receptor 3 (TLR3) polymorphism (rs1879026) and interleukin-10 (IL-10) polymorphism (rs1800896) with liver disease progression among Egyptian HCV genotype 4 patients.
methodsA case-control study was conducted involving blood samples from Egyptian HCV patients, categorized into four groups: chronic hepatitis C, cirrhosis, HCC, and a healthy control group. Genotyping of IL-10 (rs1800896) and TLR3 (rs1879026) polymorphisms was performed using TaqMan SNP assays. Standard genomic analysis methods and international guidelines have been implemented for patient recruitment and analysis.
resultsThe IL-10 rs1800896 CC genotype frequency increased progressively with disease severity, observed in 5% of controls, 26.67% fibrosis, 46.67% cirrhosis, and 66.67% HCC patients (p-value < 0.001), indicating a significant association with progression of HCV-related liver disease. In contrast, TLR3 rs1879026 genotype distribution showed no statistically significant differences across groups (p-value > 0.05).
conclusionThe IL-10 gene polymorphism (rs1800896) may contribute to genetic susceptibility in Egyptian patients, increasing the risk of HCV-related cirrhosis and HCC progression. In contrast, TLR3 rs1879026 had no clear impact on disease progression in Egyptian patients. To the best of our knowledge, this is the first report of testing the correlation between the IL-10 gene and the TLR3 polymorphism in disease progression among Egyptian HCV patients. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.